Halozyme Therapeutics, Inc. develops and operates on a biopharmaceutical technology platform in various regions. Its products are based on the ENHANZE drug delivery technology and flagship product is Hylenex recombinant, which helps to enhance the dispersion and absorption of other injected drugs. The company also develops a range of other drugs for the treatment of several diseases, and has collaborations with various industry players for the treatment and prevention of HIV.